Porta C - Search Results

1

Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients.

Porta C, Paglino C, Imarisio I, Ganini C, Sacchi L, Quaglini S, Giunta V, De Amici M. Porta C, et al. Oncology. 2013;84(2):115-22. doi: 10.1159/000342099. Epub 2012 Nov 15. Oncology. 2013. PMID: 23154434

2

Weekly taxanes in metastatic breast cancer (review).

Zimatore M, Danova M, Vassallo E, Porta C, Macaluso MC, Schittone L, Riccardi A, Palmeri S. Zimatore M, et al. Among authors: porta c. Oncol Rep. 2002 Sep-Oct;9(5):1047-52. Oncol Rep. 2002. PMID: 12168071 Review.

3

Impact of topotecan-based chemotherapy on the immune system of advanced ovarian cancer patients: an immunophenotypic study.

Ferrari S, Rovati B, Cucca L, Scarabelli C, Presti M, Beccaria C, Collovà E, Porta C, Danova M. Ferrari S, et al. Among authors: porta c. Oncol Rep. 2002 Sep-Oct;9(5):1107-13. Oncol Rep. 2002. PMID: 12168081

4

Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study.

Porta C, Zimatore M, Imarisio I, Natalizi A, Sartore-Bianchi A, Danova M, Riccardi A. Porta C, et al. Cancer. 2004 May 15;100(10):2132-8. doi: 10.1002/cncr.20226. Cancer. 2004. PMID: 15139055 Free article. Clinical Trial.

5

Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients.

Sartore-Bianchi A, Soriani A, Mattioni R, Vaglio A, Buzio C, Porta C. Sartore-Bianchi A, et al. Among authors: porta c. Oncol Rep. 2004 Oct;12(4):855-9. Oncol Rep. 2004. PMID: 15375512

6

Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients.

Porta C, Imarisio I, De Amici M, Bonomi L, Paglino C, Biscaldi E, Zimatore M, Sartore-Bianchi A, Danova M, Moratti R, Riccardi A. Porta C, et al. Oncol Rep. 2005 Apr;13(4):689-95. Oncol Rep. 2005. PMID: 15756443

7

Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.

Porta C, Zimatore M, Bonomi L, Imarisio I, Paglino C, Sartore-Bianchi A, Mutti L. Porta C, et al. Lung Cancer. 2005 Jun;48(3):429-34. doi: 10.1016/j.lungcan.2004.11.015. Epub 2005 Jan 24. Lung Cancer. 2005. PMID: 15893013 Clinical Trial.

8

Flow cytometric analysis of circulating dendritic cell subsets and intracellular cytokine production in advanced breast cancer patients.

Ferrari S, Malugani F, Rovati B, Porta C, Riccardi A, Danova M. Ferrari S, et al. Among authors: porta c. Oncol Rep. 2005 Jul;14(1):113-20. Oncol Rep. 2005. PMID: 15944777

9

Sigmoid colon metastasis from sarcomatoid renal cell carcinoma.

Invernizzi R, Bencardino K, Porta C, Vercelli A, Viglio A, Manzoni M, Sagrada P, Danova M. Invernizzi R, et al. Among authors: porta c. Tumori. 2006 May-Jun;92(3):246-8. doi: 10.1177/030089160609200312. Tumori. 2006. PMID: 16869245

10

Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells.

Porta C, Bonomi L, Lillaz B, Paglino C, Rovati B, Imarisio I, Morbini P, Villa C, Danova M, Mensi M, Rovereto B. Porta C, et al. Anticancer Res. 2007 Jan-Feb;27(1A):165-73. Anticancer Res. 2007. PMID: 17352228 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

986 results

Search Page

Filters